Last updated on November 2017

Tralokinumab monotherapy for moderate to severe atopic dermatitis.


Brief description of study

Tralokinumab monotherapy for moderate to severe atopic dermatitis.

Detailed Study Description

Tralokinumab monotherapy for moderate to severe atopic dermatitis.

Clinical Study Identifier: TX14953

Contact Investigators or Research Sites near you

Start Over

Jenna Spatz

Psoriasis Treatment Center of Central New Jersey
East Windsor, NJ USA